These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12768912)

  • 1. Ethics and equipoise: rationale for a placebo-controlled study design of platelet glycoprotein IIb/IIIa inhibition in coronary intervention.
    Tcheng JE; Madan M; O'Shea JC; Cohen EA; Buller CE; Lincoff AM; Popma JJ; Teirstein PS; Kitt MM; Lorenz TJ; Greenberg S; Fost N; Califf RM
    J Interv Cardiol; 2003 Apr; 16(2):97-105. PubMed ID: 12768912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal.
    Mann H; London AJ; Mann J
    Clin Trials; 2005; 2(3):233-41; discussion 242-3. PubMed ID: 16279146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eptifibatide in percutaneous coronary intervention. A review.
    Dery JP; O'Shea JC; Tcheng JE
    Minerva Cardioangiol; 2002 Oct; 50(5):531-46. PubMed ID: 12384635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
    Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of eptifibatide in patients undergoing percutaneous coronary intervention.
    Zeymer U
    Expert Opin Pharmacother; 2007 Jun; 8(8):1147-54. PubMed ID: 17516878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention.
    O'Shea JC; Buller CE; Cantor WJ; Chandler AB; Cohen EA; Cohen DJ; Gilchrist IC; Kleiman NS; Labinaz M; Madan M; Hafley GE; Califf RM; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2002 Feb; 287(5):618-21. PubMed ID: 11829701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa.
    O'Shea JC; Tcheng JE
    Expert Opin Pharmacother; 2002 Aug; 3(8):1199-210. PubMed ID: 12150697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Lessons from the ESPRIT study.
    Fernandes LS; Tcheng JE; O'Shea JC; Weiner B; Lorenz TJ; Pacchiana C; Berdan LG; Maresh KJ; Joseph D; Madan M; Mann T; Kilaru R; Hochman JS; Kleiman NS;
    J Am Coll Cardiol; 2002 Sep; 40(6):1085-91. PubMed ID: 12354432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: the ESPRIT trial: a randomized controlled trial.
    O'Shea JC; Hafley GE; Greenberg S; Hasselblad V; Lorenz TJ; Kitt MM; Strony J; Tcheng JE;
    JAMA; 2001 May; 285(19):2468-73. PubMed ID: 11368699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet inhibitors in non-ST-segment elevation acute coronary syndromes and percutaneous coronary intervention: glycoprotein IIb/IIIa inhibitors, clopidogrel, or both?
    Silva MA; Donovan JL; Gandhi PJ; Volturo GA
    Vasc Health Risk Manag; 2006; 2(1):39-48. PubMed ID: 17319468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of glycoprotein IIb/IIIa-receptor inhibitors during percutaneous coronary intervention.
    Cheng JW
    Am J Health Syst Pharm; 2002 Nov; 59(21 Suppl 7):S5-14. PubMed ID: 12434710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial.
    Lincoff AM; Harrington RA; Califf RM; Hochman JS; Guerci AD; Ohman EM; Pepine CJ; Kopecky SL; Kleiman NS; Pacchiana CM; Berdan LG; Kitt MM; Simoons ML; Topol EJ
    Circulation; 2000 Sep; 102(10):1093-100. PubMed ID: 10973836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.
    Cohen DJ; O'Shea JC; Pacchiana CM; Levine G; Sarembock I; Slater J; Conn E; Smith J; Tcheng JE;
    Am J Cardiol; 2002 Jan; 89(1):61-4. PubMed ID: 11779525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.